Report 28: Vaccine Trials for Infants and Children Show Little to No Benefit
Vaccine Trials for Infants and Children Show Little to No Benefit
On June 15, 2022, the FDA Vaccines and Related Biological Products Advisory Committee (VRBPA) met to authorize the expansion of the EUA Pfizer BNT162b2 vaccine to children as young as 6 months. Evidence and public comments were given, but despite the FDA accepting that the evidence for this action was poor (given a grade of C), they decided to extend the EUA to this group.
Why are we concerned about young children receiving a vaccine that we have been told is ‘safe and effective’?
As confirmed in a letter to the FDA committee by the Children’s Health Defense (RFKennedy jr, 2022), there are virtually no deaths in children under 5 from COVID and a 99.995% recovery rate for children without an underlying condition.
The vaccine does not prevent infection or reduce transmission. Furthermore, CDC published data show a poor efficacy of 31%, reducing to 12% after 7 weeks in the 5-11 yr age range (Dorabawila 2002). The mRNA vaccines do not stop infection, replication, or spread of the Omicron variants. They are not fulfilling their intended purpose.
How do we determine whether the benefits outweigh the risks in young children?
As infants and young children are so unlikely to be seriously ill or die from COVID, what are the potential risks? Sure, there are similar general effects following vaccination of pain and fever, but there are other rarer risks of serious adverse events, including respiratory problems and seizures. This is in addition to the effects on the Thymus (which is maturing and plays a major part in immunity in young children).
What did the Pfizer trial show?
Run at 65 trial sites, they recruited a total of 4526 children of which, 3000 children dropped out before the end of the trial.
Pfizer presented evidence that the only antibodies produced in the children were to the Wuhan (alpha strain) spike with no detectable antibodies to the Omicron variant (Craig, HART group, 2022).
However, the trial also shows other alarming results.
There were 30% more covid cases in the vaccine arm after first dose than the placebo, so they ignored that data. The same occurred with the second and third rounds.
In total, after 2 months, COVID developed twice as much in the vaccinated vs placebo group, suggesting that there was a higher likelihood that the vaccine was causing severe COVID than the likelihood that it was not. In fact, 12 of the children got COVID twice, 11 of which were in the vaccination arm!
What should parents take away from the results of this trial?
There is a lack of evidence to support giving the BNT162b2 COVID vaccine to children 6 months – 4 years.
The risks vastly outweigh the benefits.
Parents should be demanding decision makers at the FDA/CDC to explain themselves as to why they ignored the data and put their child at risk from adverse events, when they are so unlikely to get severe illness or die from COVID.
Dr Craig published a video de-constructing the trial (Craig, 2022).
Statement from Gov Ron DeSantis – https://youtu.be/fyad-OVxqho